European Medicines Agency (EMA) accepts new weight loss drug (Lorques-lorcaserin) for marketing review
  • Blog Home
  • Uncategorized
  • European Medicines Agency (EMA) accepts new weight loss drug (Lorques-lorcaserin) for marketing review

Many millions of Americans struggle with weight. Some of us know that QNEXA (phentermine + topiramate) could get the FDA nod as soon as April 17th, but there is another drug which you should know about. Arena Pharmaceuticals has investigated a novel drug called lorcaserin (brand would be Lorques) which shows promise. The company has announced that the European Medicines Agency (EMA) accepted the filing of a Marketing Application Application (MAA).

Time will tell how EMA will move, but the FDA also has a date with this drug. The FDA will re-review lorcaserin via the Endocrinologic and Metabolic Drugs Advisory Committee on May 10, 2012. This editor is preparing a new eBook covering QNEXA and is considering a review of lorcaserin.

Comments: